Sugi Predict

Sugi Predict / Compounds / SCHEMBL19205759

SCHEMBL19205759

SCHEMBL19205759

CCc1ccccc1-c1nccnc1-c1ccc(NC(=O)Cc2ccc(C(F)(F)[C@H](C)O)cc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ RORC P51449 12/20 0.42
▸ WNT3A P56704 1/20 0.42
▸ RET P07949 2/20 0.40
▸ ADRB2 P07550 1/20 0.40
▸ ADRB1 P08588 1/20 0.40
▸ ADRB3 P13945 1/20 0.40
▸ CYP2D6 P10635 1/20 0.39
▸ PSEN1 P49768 1/20 0.39
▸ PSEN2 P49810 1/20 0.39
▸ APH1B Q8WW43 1/20 0.39
▸ NCSTN Q92542 1/20 0.39
▸ APH1A Q96BI3 1/20 0.39
▸ PSENEN Q9NZ42 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ TRPV1 Q8NER1 1/20 0.39
▸ KCNJ5 P48544 1/20 0.39
▸ KCNJ3 P48549 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29470977 1.00 RORC (0.42) RORCWNT3ARETADRB2ADRB1
SCHEMBL29470980 1.00 RORC (0.42) RORCWNT3ARETADRB2ADRB1
SCHEMBL29471014 1.00 RORC (0.42) RORCWNT3ARETADRB2ADRB1
SCHEMBL29470978 1.00 RORC (0.42) RORCWNT3ARETADRB2ADRB1
SCHEMBL19205716 1.00 RORC (0.42) RORCWNT3ARETADRB2ADRB1
SCHEMBL18448791 1.00 RORC (0.42) RORCWNT3ARETADRB2ADRB1
SCHEMBL26382805 0.90 RORC (0.42) RORCWNT3ARETADRB2ADRB1
SCHEMBL18449666 0.89 RORC (0.44) RORCWNT3ARETCYP2D6PSEN1
SCHEMBL21133947 0.88 RORC (0.44) RORCWNT3ARETCYP2D6PSEN1
SCHEMBL29471013 0.88 RORC (0.46) RORCWNT3ARETCYP2D6PSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240108617-A1 AN INHALABLE DRY POWDER COMPOSITION FOR PULMONARY DISEASES GLENMARK SPECIALTY S.A. (CH) 2024-04-04 — — US claimed
US-20230312486-A1 POLYMORPHIC FORMS OF A ROR INHIBITING COMPOUND AND PROCESSES FOR ITS PREPARATION GLENMARK SPECIALTY S.A. (CH) 2023-10-05 — — US claimed
CN-116669733-A Polymorphic forms of rorgamma inhibiting compounds and methods of making the same 格兰马克专业公司 2023-08-29 — — CN claimed
EP-4208449-A1 POLYMORPHIC FORMS OF A RORGAMMA INHIBITING COMPOUND AND PROCESSES FOR ITS PREPARATION Glenmark Specialty S.A. (CH) 2023-07-12 — — EP claimed
CN-108026050-B Novel compounds as ROR gamma modulators 格兰马克药品股份有限公司 2021-04-30 — — CN claimed
WO-2021070150-A1 AN INHALABLE DRY POWDER COMPOSITION FOR PULMONARY DISEASES GLENMARK SPECIALTY S.A. (CH) 2021-04-15 — — WO claimed
EP-3331863-B1 NOVEL COMPOUNDS AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS SA (CH) 2020-03-11 — — EP claimed
US-10344024-B2 Compounds as ROR gamma modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2019-07-09 — — US claimed
US-20180237428-A1 NOVEL COMPOUNDS AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS SA (CH) 2018-08-23 — — US claimed
US-9975887-B2 Compounds as ROR gamma modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2018-05-22 — — US claimed
US-20170233380-A1 NOVEL COMPOUNDS AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2017-08-17 — — US claimed
US-20240108617-A1 AN INHALABLE DRY POWDER COMPOSITION FOR PULMONARY DISEASES GLENMARK SPECIALTY S.A. (CH) 2024-04-04 — — US disclosed
US-20240108617-A1 AN INHALABLE DRY POWDER COMPOSITION FOR PULMONARY DISEASES GLENMARK SPECIALTY S.A. (CH) 2024-04-04 — — US disclosed
US-20230312486-A1 POLYMORPHIC FORMS OF A ROR INHIBITING COMPOUND AND PROCESSES FOR ITS PREPARATION GLENMARK SPECIALTY S.A. (CH) 2023-10-05 — — US disclosed
US-20230312486-A1 POLYMORPHIC FORMS OF A ROR INHIBITING COMPOUND AND PROCESSES FOR ITS PREPARATION GLENMARK SPECIALTY S.A. (CH) 2023-10-05 — — US disclosed
US-20180237428-A1 NOVEL COMPOUNDS AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS SA (CH) 2018-08-23 — — US disclosed
US-9975887-B2 Compounds as ROR gamma modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2018-05-22 — — US disclosed
US-9975887-B2 Compounds as ROR gamma modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2018-05-22 — — US disclosed
US-20170233380-A1 NOVEL COMPOUNDS AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2017-08-17 — — US disclosed
US-20170233380-A1 NOVEL COMPOUNDS AS ROR GAMMA MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2017-08-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10344024-B2 Compounds as ROR gamma modulators RORB, RORA, RORC RORC 3/4885WNT3A 1508/4885RET 358/4885
US-20230312486-A1 POLYMORPHIC FORMS OF A ROR INHIBITING COMPOUND AND PROCESSES FOR ITS PREPARATION RORA, RORB, RORC RORC 3/4885WNT3A 978/4885RET 301/4885
US-20240108617-A1 AN INHALABLE DRY POWDER COMPOSITION FOR PULMONARY DISEASES H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, AGTR2, CFTR RORC 2238/4885WNT3A 3166/4885RET 3635/4885
US-20180237428-A1 NOVEL COMPOUNDS AS ROR GAMMA MODULATORS RORB, RORA, RORC RORC 3/4885WNT3A 2018/4885RET 254/4885
US-20170233380-A1 NOVEL COMPOUNDS AS ROR GAMMA MODULATORS RORB, RORA, RORC RORC 3/4885WNT3A 1460/4885RET 359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback